| Literature DB >> 25440061 |
Cynthia Hong1, Stephanie M Marshall2, Allison L McDaniel2, Mark Graham3, Joseph D Layne4, Lei Cai4, Elena Scotti1, Rima Boyadjian1, Jason Kim5, Brian T Chamberlain6, Rajendra K Tangirala5, Michael E Jung6, Loren Fong7, Richard Lee3, Stephen G Young8, Ryan E Temel9, Peter Tontonoz10.
Abstract
The LXR-regulated E3 ubiquitin ligase IDOL controls LDLR receptor stability independent of SREBP and PCSK9, but its relevance to plasma lipid levels is unknown. Here we demonstrate that the effects of the LXR-IDOL axis are both tissue and species specific. In mice, LXR agonist induces Idol transcript levels in peripheral tissues but not in liver, and does not change plasma LDL levels. Accordingly, Idol-deficient mice exhibit elevated LDLR protein levels in peripheral tissues, but not in the liver. By contrast, LXR activation in cynomolgus monkeys induces hepatic IDOL expression, reduces LDLR protein levels, and raises plasma LDL levels. Knockdown of IDOL in monkeys with an antisense oligonucleotide blunts the effect of LXR agonist on LDL levels. These results implicate IDOL as a modulator of plasma lipid levels in primates and support further investigation into IDOL inhibition as a potential strategy for LDL lowering in humans.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25440061 PMCID: PMC4261644 DOI: 10.1016/j.cmet.2014.10.001
Source DB: PubMed Journal: Cell Metab ISSN: 1550-4131 Impact factor: 27.287